A recent review highlights how the Mediterranean diet can reduce inflammation and improve outcomes for chronic skin ...

Incyte Corporation (NASDAQ:INCY) released topline results from its pivotal Phase 3 STOP-HS clinical trial program of ...

Newly released data from the phase 3 STOP-HS clinical trial program reveal positive results in hidradenitis suppurativa from ...

Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...

Beyond the surface of your skin, eczema, psoriasis and more can majorly impact your self image and intimate relationships.

Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as ...

Povorcitinib is an oral Janus kinase 1 selective inhibitor that works to reduce the overactive inflammatory signaling pathway seen in HS.

The US company’s two simultaneous trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.

Shares of Incyte sank Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.

Marketing and sales expenses increased by €2.8 million in 2024 compared to 2023, as 2024 represented the first full year of commercial efforts for GOHIBIC (vilobelimab) in the United States. In 2023, ...

Incyte said on Monday its experimental drug has met the main goal in two separate late-stage studies testing it in patients with an inflammatory skin condition called hidradenitis suppurativa.